Article
Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors.
Pharmaceutical Discovery Division, SRI International, Menlo Park, CA 94025, USA.
European Journal of Pharmacology (impact factor:
2.52).
10/2001;
428(1):29-36.
DOI:10.1016/S0014-2999(01)01282-1
pp.29-36
Source: PubMed
-
Citations (0)
- Cited In (4)
-
Article: Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes.
[show abstract] [hide abstract]
ABSTRACT: Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. Cognition refers to a capacity for information processing, applying knowledge, and changing preferences. It involves memory, attention, executive functions, perception, language, and psychomotor functions. The term nootropics was coined in 1972 when memory enhancing properties of piracetam were observed in clinical trials. In the meantime, hundreds of drugs have been evaluated in clinical trials or in preclinical experiments. To classify the compounds, a concept is proposed assigning drugs to 19 categories according to their mechanism(s) of action, in particular drugs interacting with receptors, enzymes, ion channels, nerve growth factors, re-uptake transporters, antioxidants, metal chelators, and disease modifying drugs meaning small molecules, vaccines, and monoclonal antibodies interacting with amyloid-β and tau. For drugs whose mechanism of action is not known, they are either classified according to structure, e.g., peptides, or their origin, e.g., natural products. This review covers the evolution of research in this field over the last 25 years.Journal of Alzheimer's disease: JAD 10/2012; · 3.74 Impact Factor -
Dataset: Froestl 2012 Part1
-
Dataset: Froestl 2012 Part1
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
appropriate structural modifications
available neuroleptics
different effect
functional activity
lipophilic cyclooctylmethyl moiety
nociceptin/ORL1 ligand-receptor system
Nociceptin/orphanin FQ
opiate ligands
opioid receptor system
opioid receptors
opioid-receptor
oripavine class
ORL1 receptor
ORL1 receptor affinity
ORL1 receptor ligand binding pocket
ORL1 receptor ligand design
pharmaceutical companies
piperidine N-substituents
sequence homology
small-molecule ORLI receptor ligands